Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cytheris has reported results of Phase II study indicating that recombinant Interleukin-7 (CYT107) expands CD4 T-cells in gut mucosa of chronically HIV infected immunological non-responder patients.
Subscribe to our email newsletter
The Data from INSPIRE 2 HIV study showed that CYT107 administration can expand CD4 and CD8 T-cells while increasing the expression of gut homing molecules that may result in the restoration of the CD4 T-cell population of the gut mucosa.
The results demonstrate the importance of IL-7 in stimulating T-cell repopulation of the lymphoid tissue layer in the mucosa of the gastro-intestinal (GI) tract.
Mc Gill Hospitalstudy investigator Jean Routysaid CD4 T cell depletion in the gut mucosa is an important pathogenic event in HIV infection that is associated with T-cell activation and partially restored by ART.
"The results of the current study indicate that r-hIL-7 administration can expand gut T lymphocyte numbers, predominantly central memory CD4+ T-cells," Routy added.